Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HMGCR | P04035 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22064868 | 0.77 | KDM4E (0.44) | KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL19003161 | 0.77 | KDM4E (0.44) | KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL3909195 | 0.76 | ALDH1A1 (0.43) | KDM4EKMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL21501800 | 0.67 | POLB (0.37) | KDM4ESMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL20653786 | 0.66 | KDM4E (0.40) | KDM4EAKT1 | |
| SCHEMBL22606902 | 0.65 | CA1 (0.35) | KDM4EMEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL22957136 | 0.65 | CA1 (0.35) | KDM4EMEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL22966529 | 0.65 | CA1 (0.39) | KDM4EMEN1CYP1A2KMT2ASMN1; SMN2 | |
| SCHEMBL11251896 | 0.65 | KMT2A (0.40) | KDM4EKMT2AALDH1A1 | |
| SCHEMBL25488050 | 0.63 | LMNA (0.36) | KDM4ECYP1A2SMN1; SMN2AKT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200181101-A1 | BENZAMIDE INHIBITORS OF BACTERIAL LIPOPROTEIN SIGNAL PEPTIDASE | SCRIPPS RESEARCH INST (US) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181101-A1 | BENZAMIDE INHIBITORS OF BACTERIAL LIPOPROTEIN SIGNAL PEPTIDASE | LPL, LIPE, LYPLA2 | KDM4E 3875/4885MEN1 4096/4885CYP1A2 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.